Introduction {#s1}
============

The main physiological role of vitamin D has long been regarded as regulation of calcium and phosphorous homeostasis and proper bone mineralization. In more recent years, however, inadequate vitamin D status has been linked to a number of non-skeletal chronic health conditions such as diabetes, cancer, and cardiovascular disease (CVD) ([@B1]--[@B3]). The prevalence of vitamin D deficiency is high in populations across the globe and an additional 30--50% are at risk of being vitamin D deficient ([@B4], [@B5]). Aging is also associated with decreased vitamin D synthesis in the body, putting individuals already vulnerable at an increased risk of these conditions ([@B6]).

Observational studies have consistently found an association between low serum 25-hydroxyvitamin D (25(OH)D) concentrations and presence of CVD risk factors, including blood pressure, dyslipidemia, and inflammation ([@B7]--[@B11]). A review of prospective studies found that serum 25(OH)D concentrations \<25 or 37 nmol/L (10 or 15 ng/mL) were associated with an increased risk of CVD disease or mortality ([@B12]). This is supported by a recent meta-analysis that revealed a significant association between low 25(OH)D concentration and increased cardiovascular mortality, a consistent finding across countries, sexes, age groups, and season of blood testing ([@B13]).

Current evidence suggests a role for several different vitamins in the protection of proper heart function, especially those with antioxidant potency, and thus multiple vitamin deficiencies may contribute to development of CVD. Antioxidant vitamins such as vitamin C and vitamin E might diminish the rate of oxidative stress which is a crucial component in the pathogenesis of atherosclerosis and CVD. B vitamins, which play a role in ATP energy production, and vitamin D all induce cardioprotective effects and maintain cardiovascular health ([@B14]). B vitamins might inhibit homocysteine mediated superoxide production and attenuate the atherogenicity of homocysteine ([@B15]), and improve endothelial function through decreasing homocysteine levels leading to increased flow-mediated vasodilation ([@B16]). The presence of vitamin D receptor expression in endothelial cells, vascular smooth muscle cells, and cardiac myocytes provides biological support for these observations ([@B17]); vitamin D has also been associated with the improvement of endothelial function and glucose homeostasis, reduction of oxidative stress, inflammatory response, and thrombogenesis, as well as the modulation of calcium and lipoprotein metabolism ([@B18]). Secondary hyperparathyroidism, excess parathyroid hormone, resulting from chronic vitamin D deficiency has been associated with CVD potentially through several different pathological pathways, including: (1) increased insulin resistance and pancreatic β cell dysfunction, leading to metabolic syndrome and diabetes, (2) activation of renin-angiotensin-aldosterone system (RAAS), increasing blood pressure, leading to apoptosis and fibrosis, and (3) stimulation of systemic and vascular inflammation leading to atherogenesis ([@B4], [@B19]). Current evidence suggests vitamin D deficiency is an important new cardiovascular risk factor that may play a causal role in the development of cardiovascular disease ([@B20]).

Several published meta-analyses and systematic reviews have found no beneficial effect of vitamin D supplementation on CVD risk factors ([@B21]--[@B26]). Ford ([@B24]), for example, suggested that there is insufficient evidence to support vitamin D supplementation for the reduction of cardiovascular events, although these authors did raise the possibility that vitamin D supplementation might have an effect on heart failure. Several meta-analyses and systematic reviews have similarly failed to find an association. In their systematic review, Wang et al. ([@B26]) showed a statistically nonsignificant reduction in cardiovascular disease with moderate doses of vitamin D (approximately 1,000 IU/d). Mao et al. ([@B25]) showed that neither vitamin D supplementation nor calcium supplementation had an effect on major cardiovascular events, myocardial infarction, or stroke. However, a meta-analysis is only as good as the quality of studies included.

The quality of the RCTs included in these meta-analyses has been criticized ([@B27]). Many RCTs do not have the ability to detect any effect due to an effect size that is simply too narrow ([@B28]). Several RCTs provided vitamin D doses that are far too low to measure a detectable increase in serum 25(OH)D concentration ([@B29]--[@B31]) and/or are too short in duration (e.g., weeks rather than months or years) to expect a change in health outcomes ([@B32], [@B33]). Further, most of the RCTs were grossly underpowered to detect changes in secondary outcomes ([@B28]). Several of the studies do not report baseline and/or follow-up serum 25(OH)D concentrations making it impossible to determine whether a change in vitamin D status occurred and thus whether it can be implicated in observed outcomes.

Given these uncertainties, the question of whether vitamin D supplementation improves cardiovascular risk factors and reduces subsequent disease remains without a convincing answer. The current meta-analysis investigates the role of vitamin D supplementation on cardiovascular outcomes by imposing a stringent set of inclusion criteria for studies by aggregating trials that properly take into account the biology of vitamin supplementation and by understanding the implications of different study designs.

Methods {#s2}
=======

Review design
-------------

We conducted a systematic review based on a predefined protocol registered with PROSPERO, International Prospective Register of Systematic Reviews (<http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015025346>). We included randomized controlled trials that reported blood pressure, total cholesterol, triglyceride, high and low density lipoproteins (HDL and LDL, respectively), as well as parathyroid hormone (PTH) and high sensitivity C-reactive protein (hs-CRP), peak wave velocity (PWV), and augmentation index (AI).

Search strategy
---------------

We searched Medline, the Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Excerpta Medica database (EMBASE) and gray literature (i.e., material not published in scientific, peer-reviewed journals) using Google and Google Scholar. We also searched the references of previously published systematic reviews and meta-analyses in this area. The search interval spanned January 1, 1992 through December 31, 2017. Search terms included *vitamin D, vitamin D3, and cholecalciferol* combined with *blood pressure, hypertension, cardiovascular, heart disease, coronary disease, lipids, cholesterol, triglycerides, HDL, LDL, hs-CRP, inflammation, PTH, arterial stiffness, PWV, AI* and *randomized controlled trial*. Studies were limited to those published in English.

Study selection
---------------

### Inclusion criteria

Only studies that met the following criteria were considered for this systematic review and meta-analysis: (1) studies included participants with any baseline 25(OH)D level; (2) studies recorded changes in blood pressure, PTH, hs-CRP, lipid profile, peak wave velocity, and/or augmentation index; (3) a minimum of 3 months of supplementation/therapy to ensure that the intervention had sufficient time to produce an effect on serum 25(OH)D concentrations; (4) studies with daily, weekly, or monthly frequency of dosage; (5) studies reported pre- and post-serum 25(OH)D levels (or when it was supplied by authors following request); (6) studies with control groups using a placebo and those receiving placebo plus a co-intervention (if both arms of the study received the co-intervention); and (7) studies using vitamin D~3~ or cholecalciferol.

### Exclusion criteria

Studies were excluded if: (1) they were nonclinical studies, observational studies, case-control, or cross-sectional studies; (2) they were methodological reports, editorials, narrative reviews, comments, and letters; (3) participants were younger than 18 years old; (4) intervention periods were less than 3 months; (5) dosage was less frequent than monthly or if a bolus dose was used; and (6) studies provided inadequate information on outcomes or serum 25(OH)D levels; (7) studies showed on improvement in vitamin D status (serum 25(OH)D change over time ≤ 0).

Two authors (NM, JR) independently reviewed each reference title and abstract to determine whether the studies met the inclusion criteria. Any disagreements with study selection were resolved through the discussion with the third author (SMK). Full-text articles were retrieved for the selected abstracts. Full articles were again assessed by the two independent authors (NM, JR) to ensure that they were eligible to be included in meta-analysis and any disagreements were finalized by the third author (SMK).

Data extraction
---------------

Two independent authors (NM, JR) extracted the following data from the included trials: first author and year of publication; number, age, and sex of participants; study population characteristics; latitude of residence, dosage details of vitamin D including frequency, duration and IU; any co-intervention; pre- and post-serum 25(OH)D levels; pre- and post-measures for blood pressure, PTH, hs-CRP, total cholesterol, LDL, HDL, triglycerides, PWV, and AI. NM or JR also contacted several authors to provide missing data or to clarify data within the primary report. All data was then reviewed by the third author (SMK).

Risk for bias assessment
------------------------

We assessed each included study for risk of bias by using fields from the Cochrane checklist ([@B34]) to determine the following variables: quality of random allocation concealment, blinding of outcomes assessors, treatment and control group comparability, clear definition of inclusion and exclusion criteria, participant blinding to allocation, selective reporting, if intention-to-treat analysis applied, and description of withdrawals and dropouts. Each criterion was marked as (+) with adequate information, (−) with inadequate information and (?) with unclear information (Table [S1](#SM1){ref-type="supplementary-material"}).

We generated Begg funnel plots to visually examine possible publication bias. These plots were supplemented by formal statistical testing using the Egger weighted regression tests ([@B35]). The analysis for the effects of publication bias was adjusted using the Duval and Tweedie trim-and-fill method ([@B36]).

Strategy for data synthesis and statistical analysis
----------------------------------------------------

We performed the meta-analysis at the trial level using Comprehensive Meta-Analysis V3 (Biostat 2014, Englewood, NJ) ([@B37]). To calculate the effect size, the mean change in concentrations, calculated as measure at the end of intervention minus measure at baseline, and the standard deviation of the outcomes were used for both treatment groups ([@B38]) and the effect size was expressed as standardized mean difference between vitamin D intervention and placebo groups, with a 95% confidence interval. For all treatment effects, a negative value denoted a reduction in the outcomes within the vitamin D group compared with placebo. We used the *I*^2^ index to evaluate heterogeneity among the included studies and with a value ≥50%, random-effects model (using the DerSimonian--Laird and generic inverse variance method) was applied ([@B39], [@B40]).

We conducted a sensitivity analysis using the leave-one-out method to assess the effect of each study on the overall effect size ([@B41]). For studies with more than one vitamin D supplemented group (e.g., different daily doses given), the trial with the higher dose was selected and compared with the placebo group.

Subgroup analysis
-----------------

To further assess interactions among subgroup treatments and also to address heterogeneity among included studies, we defined *a priori* subgroups as followed: participant\'s age (\<55 vs. ≥55 years old), which was the median of study population\'s age and the central value of data providing an equal distribution of information for comparison; vitamin D supplementation dose (\<4,000 vs. ≥4,000 IU/day), which is the average dose required to provide optimal serum physiological levels of vitamin D (100--130 nmol/L) ([@B30], [@B42]); serum 25(OH)D concentration at the end of the intervention (\<86 vs. ≥86 nmol/L), which was selected as the median value of serum 25(OH)D levels; duration of intervention (\<6 months vs. ≥6 months), which was selected based on the half-life of serum 25(OH)D and the time required to maintain a steady serum levels and potentially influence other biomarkers ([@B43]--[@B45]); obesity (BMI \< 30 vs. BMI ≥ 30 kg/m^2^) as defined by WHO ([@B46]) and based on and the fact that obese individuals need 2--3 times the amount of vitamin D to achieve the same serum 25(OH)D as normal weight individuals ([@B47]); vitamin D deficiency at the beginning of the intervention \[serum 25(OH)D \< 50 vs. ≥50 nmol/L\] as defined by IOM ([@B48]) and based on evidence demonstrating a strong association between vitamin D deficiency and higher incidence of CVD risk factors ([@B12]); and, calcium co-intervention.

Results {#s3}
=======

Study selection
---------------

We screened the titles of 2,341 studies after duplicates were removed. After excluding any irrelevant studies, 252 abstracts were retrieved for further examination. Based on the abstracts, 177 full-text articles were assessed to determine whether they satisfied the inclusion criteria. Of these, 86 were excluded from analysis because the intervention was less than 3 months intervention, the frequency of dosage was more than monthly or bolus doses were given, pre- or post-serum 25(OH)D levels were not reported, or the trials were centered on children/ adolescents.

For the other 10 trials we did not include data, they either shared similar designs and outcomes ([@B49], [@B50]), had no post serum 25(OH)D data available ([@B51]) or, even after contacting the corresponding author, had insufficient information ([@B52]--[@B58]). We only included papers where an increase in vitamin D status followed supplementation, so the Cooper et al. ([@B59]) study was excluded. Finally, 81 studies were included in systematic review and meta-analysis. Details of the complete search process and for each outcome are given in Figure [1](#F1){ref-type="fig"}.

![PRISMA diagram of study selection.](fcvm-05-00087-g0001){#F1}

Risk of bias assessment
-----------------------

Ten of the included studies lacked information on the blinding of participants and personnel, and one study did not provide information on allocation concealment. Less than half of the studies (*n* = 38) used an intent-to-treat analysis. However, the vast majority of the included studies had a low risk of bias. Details of the quality of bias assessment are provided in Table [S1](#SM1){ref-type="supplementary-material"}.

Study characteristics
---------------------

The characteristics of the included trials are given in Table [1](#T1){ref-type="table"} and studies that were excluded from the meta-analysis are highlighted. The included studies were published between 1992 and 2017. The average latitude of the studies conducted in the northern hemisphere was 43.2 ± 14.7°N (73 studies), with the maximum latitude of 70°N, and the average latitude of the studies from the southern hemisphere was 34.6 ± 6.8°S (eight studies), with the maximum latitude of 43S. Sample sizes varied from 20 ([@B61]) to 484 ([@B126]); a total of 9,993 participants are included in the meta-analysis, with 5,042 in a vitamin D-supplemented group and 4,951in a placebo group. Twenty of the studies only assessed females (Table [1](#T1){ref-type="table"}), but the overall study population included 67% females and 33% males. The mean age of participants ranged from 18 ([@B77]) to 85 years ([@B66], [@B74], [@B98], [@B104]), with an overall average age of 55 ± 15 years.

###### 

Characteristics of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
       **First author and year**                                      **N**   **Study population**                                                 **Latitude**   **Mean age**   **% male**   **BMI (kg/m^2^)**   **Daily dose (or daily dose equivalent) of Vitamin D (IU)**     **Other treatment[^1^](#TN5){ref-type="table-fn"}**   **Control group**         **Duration of supplementation**   **CVD outcomes measured**          **Mean baseline 25OHD of treatment group (nmol/l)**   **Mean post treatment 25OHD of treatment group (nmol/l)**   **Mean baseline 25OHD of placebo group (nmol/l)**   **Mean post treatment 25OHD of placebo group (nmol/l)**
  ---- -------------------------------------------------------------- ------- -------------------------------------------------------------------- -------------- -------------- ------------ ------------------- --------------------------------------------------------------- ----------------------------------------------------- ------------------------- --------------------------------- ---------------------------------- ----------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------
  1    Alvarez et al. ([@B60])                                        46      Subjects with early kidney disease                                   34 N           62             21           NA                  7,143 (12 weeks) followed by 3,571 (40 weeks) \[4,395 IU/d\]                                                          Placebo                   12 months                         BP, PTH                            67                                                    106                                                         80                                                  78

  2    Al-Sofiani et al. ([@B61])                                     20      Type 2 diabetes, insulin resistance & vitamin D deficiency           24 N           48             NA           31                  5,000                                                                                                                 Placebo                   3 months                          BP                                 24                                                    91                                                          39                                                  29

  3    Al-Zahrani et al. ([@B62])                                     183     Type 2 diabetic patients                                             24 N           55             49           32                  6,430 (2 months) followed by 1,500 (1 month) \[4,787 IU/d\]                                                           Placebo                   3 months                          BP, Lipid profile                  25                                                    83                                                          22                                                  55

  4    Arora et al. ([@B63])                                          534     Individuals 18--50 years old                                         42 N           37             69           NA                  4,000                                                                                                                 400 IU Vitamin D/day      6 months                          BP                                 39                                                    83                                                          40                                                  45

  5    Barchetta et al. ([@B64])                                      55      Type 2 diabetes patients with NAFLD                                  42 N           58             65           30                  2,000                                                                                                                 Placebo                   6 months                          Lipid profile CRP BP               43                                                    86                                                          37                                                  40

  6    Beilfuss et al. ([@B65])                                       332     Individuals 21--70 years old overweight & obese                      70 N           50             39           34                  2,143                                                           500 mg/d Ca                                           Placebo                   12 months                         PTH, hs-CRP,                       54                                                    99                                                          52                                                  50

  7    Bjorkman et al. ([@B66])                                       119     Long-term bedridden inpatients, age 65+                              60 N           85             18           NA                  400                                                             daily calcium of 500 mg                               Placebo                   6 months                          PTH, CRP                           21                                                    48                                                          24                                                  26

  8    Bolton-Smith et al. ([@B67])                                   123     Healthy, non-osteoporotic women age 60+                              56 N           68             0            NA                  400                                                             1,000 mg Ca/day (Vitamin D group only)                Placebo                   24 months                         PTH                                63                                                    75                                                          57                                                  49

  9    Boxer et al. ([@B68])                                          64      Patients with heart failure                                          41 N           66             48           NA                  7,143                                                           800 mg Ca/day                                         800 mg Ca/day             6 months                          PTH                                48                                                    153                                                         44                                                  45

  10   Breslavsky et al. ([@B69])                                     47      Diabetic patients                                                    32 N           66             47           NA                  1,000                                                                                                                 Placebo                   12 months                         BP, lipid profile, CRP, AI         30                                                    44                                                          29                                                  35

  11   Bressen dorff et al.\                                          40      Healthy adults, vitamin D deficient                                  56 N           43             23           25                  3,000                                                                                                                 Placebo                   4 months                          BP, PWV, AI                        31                                                    88                                                          32                                                  37
       ([@B33])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  12   Cangussu et al. ([@B70])                                       160     Post-menopausal women                                                23 S           59             0            NA                  1,000                                                                                                                 Placebo                   9 months                          PTH                                38                                                    69                                                          42                                                  35

  13   Carrillo et al. ([@B71])                                       23      Overweight & obese adults                                            40 N           26             48           32                  4,000                                                                                                                 Placebo                   3 months                          PTH                                52                                                    84                                                          45                                                  59

  14   Chandler et al. ([@B72])                                       149     Healthy Black population 30--80 years old                            42 N           51             34           31                  4,000                                                           200 mg/d CaCO3                                        Placebo                   3 months                          CRP                                39                                                    115                                                         38                                                  34

  15   Chapuy et al. ([@B73])                                         142     Ambulatory elderly women living in nursing homes                     42--51 N       84             0                                800                                                             1,200 mg Ca/day (Vitamin D group only)                Placebo                   18 months                         PTH                                40                                                    105                                                         33                                                  28

  16   Chapuy et al. ([@B74])                                         384     Ambulatory elderly women living in nursing homes                     42--51 N       85             0            NA                  800                                                             1,200 mg Ca/day (Vitamin D group only)                Placebo                   24 months                         PTH                                23                                                    78                                                          23                                                  18

  17   Dalan et al. ([@B52])[^\*^](#TN1){ref-type="table-fn"}         64      Type 2 diabetes with hypovitaminosis D                               1 N            53             52           28                  4,000/2,000                                                                                                           Placebo                   4 months                          PTH, BP, CRP, AI, Lipid profile    43                                                    79                                                          48                                                  48

  18   Cooper et al. ([@B59])[^\*\*^](#TN2){ref-type="table-fn"}      187     Healthy women ≥1 year postmenopausal                                 34 S           56             0                                1,429                                                           1,000 mg Ca/day                                       Placebo                   24 months                         PTH                                82                                                    81                                                          83                                                  69

  19   Daly et al. ([@B75])                                           124     Healthy, community dwelling men age 50+                              38 S           61             100          27                  800                                                             1,000 mg Ca/day (Vitamin D group only)                Placebo                   24 months                         BP, lipid profile, PTH             78                                                    83                                                          76                                                  62

  20   Dalbeni et al. ([@B76])                                        23      Chronic HF patients, vitamin D \< 75 nmol/L                          45 N           72             74           30                  4,000                                                                                                                 Placebo                   6 months                          Lipid profile, PTH, BP             43                                                    79                                                          44                                                  37

  21   Dawson-Hughes et al. ([@B72])                                  389     Healthy, community dwelling, age 65+                                 42 N           71             45           NA                  700                                                             500 mg Ca/day (Vitamin D group only)                  Placebo                   36 months                         PTH                                77                                                    112                                                         73                                                  70

  22   Dong et al. ([@B77])                                           44      Normotensive black youth                                             33 N           18             57           27                  2,000                                                                                                                 400 IU/d                  4 months                          PWV, PTH                           34                                                    86                                                          33                                                  60

  23   Dutta et al. ([@B78])                                          104     Family member of diabetic patients with IFG/IGT                      21 N           55             43           26                  8,600 (2 months) followed by 2,000 (10 months) \[3,100 IU/d\]   CaCO3 125 mg                                          Placebo                   12 months                         Lipid, CRP                         43                                                    89                                                          45                                                  44

  24   El-Hajj et al. ([@B79])                                        222     Elderly overweight, vitamin D deficient                              34 N           71             45           30                  3,750                                                           1,000 mg Ca citrate                                   600 IU/d                  12 months                         Lipid profile                      52                                                    90                                                          50                                                  65

  25   Farrokhian et al. ([@B80])                                     60      Overweight, vitamin D deficient with CAD                             34 N           62             50           30                  3,571                                                                                                                 Placebo                   6 months                          Lipid profile, CRP                 42                                                    86                                                          41                                                  42

  26   Forman et al. ([@B81])                                         142     Healthy Black population                                             42 N           51             37           31                  4,000                                                           200 mg/d Ca                                           Placebo                   3 months                          BP                                 39                                                    115                                                         41                                                  43

  27   Forouhi et al. ([@B82])                                        228     People at risk for type 2 diabetes                                   52 N           52             57           29                  3,333                                                                                                                 Placebo                   4 months                          BP, Lipid profile, CRP, PTH, PWV   46                                                    84                                                          46                                                  39

  28   Gagnon et al. ([@B83])                                         74      Pre-diabetic vitamin D deficient adults                              41 S           54             31           31                  2,000-6,000 \[4,000 IU/d\]                                      1,200 mg CaCO3                                        Placebo                   6 months                          Lipid profile, CRP                 47                                                    95                                                          43                                                  40

  29   Garg et al. ([@B84])                                           32      Women age 18--35 with PCOS                                           29 N           22             0            26                  4,000                                                           Metformin                                             Placebo                   6 months                          Lipid profile, PTH, PWV, AI        19                                                    79                                                          17                                                  17

  30   Gepner et al. ([@B85])                                         98      Post-menopausal women                                                43 N           63             0            26                  2,500                                                                                                                 Placebo                   4 months                          BP, CRP, AI, PWV                   76                                                    115                                                         81                                                  80

  31   Gepner et al. ([@B86])                                         110     Post-menopausal women                                                43 N           61             0            33                  2,500                                                                                                                 400                       6 months                          BP, CRP, AI                        68                                                    107                                                         63                                                  75

  32   Grimnes et al. ([@B87])                                        94      Healthy adults age 30--75                                            69 N           53             51           NA                  5,714                                                                                                                 Placebo                   6 months                          Lipid profile, PTH                 42                                                    143                                                         39                                                  43

  33   Harwood et al. ([@B66])[^\*^](#TN1){ref-type="table-fn"}       150     Elderly female subjects with recent hip surgery                      53 N           81             0                                800                                                             1,000 mg Ca/day (Vitamin D group only)                Placebo                   12 months                         PTH                                29                                                    50                                                          30                                                  27

  34   Hewitt et al. ([@B88])                                         60      Vitamin D deficient on hemodialysis                                  34 S           62             48           NA                  4,500                                                                                                                 Placebo                   6 months                          PWV                                40                                                    98                                                          48                                                  50

  35   Hin et al. ([@B89])                                            203     Community dwelling elderly                                           52 N           71             51           28                  4,000                                                                                                                 Placebo                   12 months                         PTH                                49                                                    137                                                         47                                                  53

  36   Holmoy et al. ([@B90])                                         68      Patients with relapsing remitting MS                                 60 N           40             29           26                  2,857                                                           500 mg Ca/day                                         Placebo                   24 months                         PTH                                55                                                    123                                                         57                                                  62

  37   Islam et al. ([@B91])                                          75      Healthy women age 16--36                                             24 N           23             0            22                  400                                                                                                                   Placebo                   12 months                         Lipid profile                      37                                                    69                                                          35                                                  35

  38   Jafari et al. ([@B92], [@B93])                                 59      Post-menopausal women with type 2 diabetes                           32 N           57             0            29                  2,000                                                           Yogurt drink                                          Placebo (plain yogurt)    3 months                          BP, CRP, Lipid profile, PTH        62                                                    87                                                          63                                                  56

  39   Jamilian et al. ([@B94])                                       60      PCOS women                                                           32 N           NA             0            NA                  400                                                             Plus Mg 200 mg, zinc 8 mg, calcium 800 mg             Placebo                   3 months                          Lipid profile                      33                                                    62                                                          32                                                  33

  40   Jorde and Figenschau ([@B95])                                  32      Type 2 diabetes                                                      60 N           56             56           32                  5,714                                                           Metformin, bed-time insulin                           Placebo                   6 months                          BP, PTH, Lipid profile             60                                                    119                                                         59                                                  57

  41   Jorde et al. ([@B49])[^\#^](#TN3){ref-type="table-fn"}         438     Overweight or obese subjects                                         69 N           48             36                               5,714\                                                          500 mg Ca/day                                         Placebo                   12 months                         BP, lipid profile, PTH             58.7\                                                 140\                                                        59                                                  57
                                                                                                                                                                                                                  2,857                                                                                                                                                                                                                56.7                                                  101                                                                                                             

  42   Jorde et al. ([@B50])                                          227     Prediabetes adults                                                   60 N           62             61           30                  2,857                                                                                                                 Placebo                   5 years                           PTH, BP, Lipid profile             60                                                    122                                                         61                                                  67

  43   Kamycheva et al. ([@B96])                                      215     Overweight or obese subjects age 21-70 years                         69 N           49             35           35                  5,714                                                           500 mg/d Ca                                           Placebo                   12 months                         PTH                                56                                                    116                                                         53                                                  85

  44   Kampmann et al. ([@B54])[^\*^](#TN1){ref-type="table-fn"}      15      Adults with type 2 diabetes and hypovitaminosis D                    56 N           30             53           33.8                8,400                                                                                                                 Placebo                   3 months                          BP, Lipid profile, PTH, CRP        31                                                    105                                                         35                                                  32

  45   Kjaergaard et al. ([@B97])                                     230     Adults with 25OHD \< 55 nmol/l                                       69 N           64             45           NA                  5,714                                                                                                                 Placebo                   6 months                          PTH                                47                                                    148                                                         48                                                  53

  46   Krieg et al. ([@B98])                                          72      Women living in nursing homes                                        47 N           85             0            NA                  880                                                             1,000 mg Ca/day (Vitamin D group only)                Placebo                   24 months                         PTH                                30                                                    66                                                          29                                                  14

  47   Krul-Poel et al. ([@B99])                                      261     Adults with type 2 diabetes with no insulin treatment                52 N           67             65           29                  1,667                                                           Metformin                                             Placebo                   6 months                          BP, PTH                            61                                                    101                                                         59                                                  60

  48   Larsen et al. ([@B100])                                        112     Hypertensive patients in Denmark                                     56 N           60             31           28                  3,000                                                                                                                 Placebo                   5 months                          PTH, BP, AI, PWV                   58                                                    110                                                         58                                                  50

  49   Longenecker et al. ([@B55])[^\*^](#TN1){ref-type="table-fn"}   45      HIV-infected vitamin D deficient                                     41 N           44             75           27.5                4,000                                                           HIV meds                                              Placebo                   3 months                          CRP, PTH, BP, Lipid profile        22.5                                                  35                                                          15.5                                                11

  50   Lorvand Amiri et al. ([@B101])                                 73      Patients with NAFLD, vitamin D deficient                             36 N           40             62           30                  1,000                                                           Hypocaloric diet (500)                                Placebo                   3 months                          Lipid profile                      25                                                    68                                                          25                                                  28

  51   Macdonald et al. ([@B102])                                     179     Healthy post-menopausal women                                        57 N           65             0            NA                  1,000                                                                                                                 Placebo                   12 months                         PTH                                33                                                    76                                                          36                                                  32

  52   Major et al. ([@B51])[^\*^](#TN1){ref-type="table-fn"}                 Healthy overweight or obese women                                    47N            43             0            32                  400                                                             1,200 mg Ca/day, calorie restrict diet                Placebo                   4 months                          BP, Lipid profile                                                                                                                                                                                        

  53   Martins et al. ([@B103])                                       115     Overweight & obese African American, high BP & vitamin D deficient   34 N           43             61           ≥25                 3,333                                                                                                                 Placebo                   3 months                          BP, AI, PTH                        17                                                    35                                                          17                                                  17

  54   Mason et al. ([@B71])                                          187     Overweight & obese post- menopausal women                            47 N           60             0            32                  2,000                                                                                                                 Placebo                   12 months                         CRP                                54                                                    88                                                          60                                                  50

  55   Meyer et al. ([@B104])                                         65      Nursing home residents                                               60 N           85             25           NA                  400                                                                                                                   Placebo                   24 months                         PTH                                47                                                    64                                                          51                                                  46

  56   Moreira Lucas et al. ([@B105])                                 71      Vitamin D deficient & impaired fasting glucose adults                56 N           47             47           31                  4,000                                                                                                                 Placebo                   6 months                          BP, PTH, Lipid profile             48                                                    99                                                          48                                                  45

  57   Mose et al. ([@B106])                                          50      Patients on chronic dialysis                                         57 N           68             64           24                  3,000                                                                                                                 Placebo                   6 months                          PTH, CRP, BP, AI, PWV              28                                                    84                                                          28                                                  30

  58   Munoz-Aguirre et al. ([@B107])                                 104     Postmenopausal overweight women with diabetes                        18 N           56             0            31                  4,000                                                                                                                 Placebo                   6 months                          Lipid profile                      55                                                    85                                                          54                                                  56

  59   Nikooyeh et al. ([@B108])                                      60      Diabetic patients                                                    32 N           50             39           29                  1,000                                                                                                                 Plain yogurt, Ca 300 mg   3 months                          BP, Lipid profile                  44                                                    78                                                          42                                                  37

  60   Patel et al. ([@B109])                                         24      Type 2 diabetes & vitamin D deficiency                               41 N           58             29           32                  1,000                                                                                                                 400                       4 months                          PTH, Lipid profile                 39                                                    69                                                          44                                                  64

  61   Petchey et al. ([@B110])                                       25      Adult patients with chronic kidney disease                           27 S           66             71           NA                  2,000                                                                                                                 Placebo                   6 months                          PTH                                95                                                    146                                                         88                                                  81

  62   Pfeifer et al. ([@B111])                                       242     Community dwelling, healthy subjects age 70+                         46--52 N       77             26           NA                  800                                                             1,000 mg Ca/day                                       Placebo                   12 months                         PTH                                55                                                    84                                                          54                                                  57

  63   Pittas et al. ([@B112])                                        222     Healthy adults                                                       42 N           70             38           26                  700                                                             500 mg Ca citrate/day                                 Placebo                   3 years                           PTH, CRP                           81                                                    111                                                         71                                                  70

  64   Qin et al. ([@B113])                                           56      Statin-treated patients with hypercholesterolemia                    40 N           68             55           NA                  2,000                                                                                                                 Placebo                   6 months                          Lipid profile, PTH                 53                                                    96                                                          53                                                  59

  65   Raed et al. ([@B114])                                          35      Overweight vitamin D deficient African American                      40 N           27             18           35                  4,000                                                                                                                 Placebo                   4 months                          PWV                                33                                                    88                                                          33                                                  34

  66   Rahimi-Ardabili et al. ([@B115])                               50      PCOS women with vitamin D deficiency                                 32 N           30             0            29                  2,500                                                                                                                 Placebo                   3 months                          PTH, CRP, Lipid profile            17                                                    59                                                          20                                                  21

  67   Raja Khan et al. ([@B116])                                     28      Woman with PCOS                                                      41 N           28             0            37                  12,000                                                                                                                Placebo                   3 months                          CRP, PTH, BP, Lipid profile        50                                                    168                                                         56                                                  56

  68   Rajpathak et al. ([@B56])[^\*^](#TN1){ref-type="table-fn"}             Post-menopausal women                                                41N            65             0            29                  400                                                             1 g elemental Ca                                      Placebo                   5 years                           Lipid profile                                                                                                                                                                                            

  69   Ramly et al. ([@B117])                                         192     Vitamin D deficient pre-menopausal women                             3 N            43             0            NA                  7,143 (2 months) followed by 1,667 (10 months) \[2,580 IU/d\]                                                         Placebo                   12 months                         BP, lipid profile, PTH             30                                                    86                                                          30                                                  36

  70   Rosenblum et al. ([@B118])                                     71      Overweight & obese adults                                            42 N           40             18           30                  300                                                             Plus 1,050 mg Ca                                      Placebo                   4 months                          PTH, Lipid profile                 65                                                    77                                                          68                                                  68

  71   Ryu et al. ([@B119])                                           64      Patients type 2 diabetes                                             38 N           56             NR           NA                  2,000                                                           200 mg Ca/day                                         Placebo                   6 months                          BP, CRP, lipid profile, PTH        31                                                    86                                                          27                                                  46

  72   Sadiya et al. ([@B120])                                        82      Patients with type 2 diabetes                                        25 N           49             18           NA                  6,000 (3 months) followed by 3,000 (3 months) \[4,500 IU/d\]                                                          Placebo                   6 months                          BP, CRP, lipid profile, PTH        29                                                    62                                                          31                                                  25

  73   Salekzamani et al. ([@B121])                                   71      Healthy adults 30-50 years old                                       38 N           40             49           \<40                7,143                                                                                                                 Placebo                   4 months                          BP, lipid profile                  16                                                    78                                                          23                                                  21

  74   Salehpour et al. ([@B32])                                      77      Overweight and obese adults                                          36 N           38             0            30                  1,000                                                                                                                 Placebo                   3 months                          BP, PTH, Lipid profile             37                                                    75                                                          47                                                  52

  75   Schleithoff et al. ([@B122])                                   93      Patients with congestive heart failure                               51 N           56             83           NA                  2,000                                                           500 mg Ca/day                                         Placebo                   9 months                          BP, CRP, PTH                       36                                                    103                                                         38                                                  47

  76   Scragg et al. ([@B123])                                        304     Healthy adults                                                       43 S           48             25           NA                  6,667 (2 months) followed by 3,333 (16 month) \[3,700 IU/d\]                                                          Placebo                   18 months                         BP                                 73                                                    124                                                         71                                                  56

  77   Seibert et al. ([@B124])                                       105     Healthy adults                                                       51 N           45             33           24                  800                                                                                                                   Placebo                   3 months                          Lipid, BP                          38                                                    72                                                          38                                                  30

  78   Shab-Bidar et al. ([@B125])                                    80      Patients with type 2 diabetes                                        35 N           52             43           29                  1,000                                                           340 mg Ca/d                                           Placebo                   3 months                          BP, lipid profile,                 39                                                    72                                                          38                                                  33

  79   Sinha-Hikim et al. ([@B112])                                   80      Latino & African American with prediabetes & hypovitaminosis D       34 N           52             30           33                  12,185                                                                                                                Placebo                   6 months                          CRP                                55                                                    175                                                         55                                                  55

  80   Sollid et al. ([@B126])                                        484     Subjects with prediabetes                                            70 N           62             61           NA                  2,857                                                                                                                 Placebo                   12 months                         BP, CRP, lipid profile, PTH        60                                                    106                                                         61                                                  65

  81   Sun et al. ([@B127])                                           81      Healthy adults                                                       36 N           43             36           22                  420                                                                                                                   Placebo                   12 months                         BP, Lipid profile, PTH, CRP        33                                                    61                                                          32                                                  31

  82   von Hurst et al. ([@B57])[^\*^](#TN1){ref-type="table-fn"}     235     Women of South Asian origin living in New Zealand                    37 S           42             0                                4,000                                                                                                                 Placebo                   6 months                          BP, hsCRP, lipid profile           21                                                    80                                                          19                                                  29

  83   Tomson et al. ([@B128])                                        203     Old people living in UK                                              55 N           71             50           27                  4,000                                                                                                                 Placebo                   6 months                          BP, AI, PWV                        50                                                    137                                                         50                                                  53

  84   Toss et al. ([@B129])                                          45      Community dwelling subjects                                          58 N           70             29           NA                  1,600                                                           1,000 mg Ca/day                                       Placebo                   12 months                         PTH                                50                                                    84                                                          47                                                  46

  85   Wamberg et al. ([@B130])                                       43      Obese adults with low Vitamin D levels                               55 N           40             29           NA                  7,000                                                                                                                 Placebo                   26 weeks                          BP, CRP, lipid profile, PTH        33                                                    110                                                         34                                                  47

  86   Witham et al. ([@B131])                                        50      Patients with chronic fatigue syndrome                               56 N           49             24           29                  1,667                                                                                                                 Placebo                   6 months                          PWV, AI, BP, PTH, Lipid profile,   44                                                    64                                                          48                                                  44

  87   Wood et al. ([@B132])                                          174     Healthy post-menopausal women                                        57 N           64             0            NA                  1,000                                                                                                                 Placebo                   12 months                         BP, CRP, lipid profile, PTH        32                                                    76                                                          36                                                  32

  88   Yeow et al. ([@B133])                                          26      Women with former gestational diabetes                               5 N            36             0            NA                  4,000                                                                                                                 Placebo                   6 months                          BP, CRP, lipid profile, PTH        36                                                    92                                                          35                                                  29

  89   Yousefi Rad et al. ([@B134])                                   58      Diabetic patients                                                    32 N           50             NA           28                  4,000                                                                                                                 Placebo                   3 months                          Lipid profile                      39                                                    69                                                          37                                                  40

  90   Yiu et al. ([@B58])[^\*^](#TN1){ref-type="table-fn"}           100     Type 2 Diabetes Mellitus patients                                    22 N           65             50           25                  5,000                                                                                                                 Placebo                   3 months                          PTH, PWV, hsCRP, Lipid profile     53                                                    147                                                         55                                                  60

  91   Zitterman et al. ([@B135])                                     165     Healthy overweight subjects                                          51 N           48             33           NA                  3,332                                                                                                                 Placebo                   12 months                         BP, CRP, lipid profile, PTH        30                                                    86                                                          30                                                  42
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Given to both groups unless stated otherwise*.

*Highlighted studies were excluded from meta-analysis*,

*insufficient information*,

*no improve in serum D*,

*similar design)*.

Participants received treatment through capsules, pills, tablets, oil drops, or as a specially fortified milk or yogurt drink. Calcium was co-administered with vitamin D and placebo in 24 of the 81 studies (Table [1](#T1){ref-type="table"}). The duration of intervention lasted 3 months to 5 years, with an average duration of 9.6 ± 9.2 months (median = 6 months). The daily dose of supplemental vitamin D ranged from 400 ([@B66], [@B67], [@B91], [@B94], [@B104]) to 12,000 IU ([@B116]), with an average of 2,967 ± 2,271 IU/day. Baseline serum 25(OH)D concentration varied widely from 16 ([@B121]) to 95 nmol/l ([@B110]), with the average of 45 ± 16 nmol/L in both vitamin D and placebo groups. The diversity of participants was considerable in these studies. Some were healthy and community dwelling populations, whereas others were institutionalized and/or had specific health conditions such as diabetes, kidney disease, women with polycystic ovary syndrome (PCOS), or included patients on hemodialysis. Forty-six of the studies reported serum PTH concentrations, 39 reported blood pressure and lipid profiles, 28 studies recorded hs-CRP concentrations, and 10/11 studies PWV and AI as their outcomes.

Effect of vitamin D supplementation on serum 25(OH)D level
----------------------------------------------------------

Following vitamin D supplementation (average dose of \~3,000 IU/day), there was a significant increase in serum 25(OH)D levels in vitamin D group (48 ± 23 nmol/L) after an average of 9.6 months intervention, while it remained unchanged in placebo group (1 ± 9 nmol/L). Each of the studies reported an overall improvement in vitamin D status, with 27 recording serum 25(OH)D level greater than 100 nmol/L (Table [1](#T1){ref-type="table"}). There is a significant dose-response effect between vitamin D supplementation dose and serum 25(OH)D concentration at the end of the intervention (*R*^2^ = 0.37, *p* \< 0.001). Achieved serum 25(OH)D concentrations ≥100 nmol/L were observed in trials prescribing vitamin D at doses between 4,000 and 12,000 IU/day ([@B50], [@B60], [@B68], [@B72], [@B74], [@B81], [@B85]--[@B87], [@B89], [@B90], [@B95]--[@B97], [@B99], [@B100], [@B110], [@B112], [@B116], [@B122], [@B123], [@B126], [@B128], [@B130], [@B136], [@B137]).

Pooled estimate of the effect of vitamin D on cardiometabolic parameters
------------------------------------------------------------------------

### Vitamin D and blood pressure

A total of 39 studies reported on outcomes of systolic and diastolic blood pressure (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). The pooled effect size (standardized mean difference) of the effect of vitamin D supplementation on systolic blood pressure was −0.102 ± 0.04 mmHg, (95% CI −0.20 to −0.01, *p* = 0.02, *I*^2^ = 51%) across all studies. The pooled effect size for diastolic blood pressure was −0.072 ± 0.03 mmHg (95% CI −0.14 to −0.006, *p* = 0.03, *I*^2^ = 18%) across all studies. Overall results indicated that vitamin D supplementation was significantly associated with lower blood pressure.

![Forest plot detailing standardized mean difference for the impact of vitamin D on systolic blood pressure.](fcvm-05-00087-g0002){#F2}

![Forest plot detailing standardized mean difference for the impact of vitamin D on diastolic blood pressure.](fcvm-05-00087-g0003){#F3}

Six studies showed a significant reduction in systolic blood pressure ([@B61], [@B76], [@B81], [@B100], [@B121], [@B128]) and four studies revealed significant reductions in diastolic blood pressure ([@B81], [@B116], [@B125], [@B128]). Seventeen studies demonstrated a decreasing trend in systolic and/or diastolic blood pressure following vitamin D supplementation, though these changes were not statistically significant ([@B50], [@B62], [@B82], [@B86], [@B92], [@B95], [@B108], [@B116], [@B117], [@B119], [@B123]--[@B125], [@B127], [@B130], [@B131], [@B135]). The remaining 16 studies with information on systolic blood pressure ([@B32], [@B33], [@B60], [@B63], [@B64], [@B69], [@B75], [@B85], [@B99], [@B103], [@B105], [@B106], [@B120], [@B122], [@B126], [@B133]) and 19 on diastolic blood pressure ([@B32], [@B33], [@B60], [@B63], [@B64], [@B75], [@B76], [@B82], [@B92], [@B99], [@B103], [@B106], [@B119], [@B120], [@B124], [@B126], [@B127], [@B133], [@B135]) showed either a null effect or an increase in blood pressure. In the majority of these studies, blood pressure was a secondary endpoint and the studies were not designed or powered for detecting the effects of vitamin D supplementation on blood pressure. Some studies also included patients with comorbid condition like kidney ([@B60], [@B106]) or heart failure ([@B122]), and others had all or a majority of their participants with normal blood pressure at baseline.

Only one of the included studies centered on hypertensive patients ([@B100]). After a five month intervention, this study found a significant reduction in blood pressure following vitamin D supplementation (3,000 IU/day) and improved serum 25(OH)D levels (50 nmol/L increase) compared to placebo.

### Vitamin D and lipid profiles

Thirty-eight papers reported on the lipid profiles of participants (Table [1](#T1){ref-type="table"}). Across all studies, vitamin D supplementation significantly decreased TG (pooled effect size −0.12 ± 0.06 mmol/L, 95% CI −0.24 to −0.003, *p* = 0.04, *I*^2^ = 64%) (Figure [4](#F4){ref-type="fig"}). Ten individual studies reported significant reductions in serum triglycerides with vitamin D supplementation ([@B50], [@B84], [@B92], [@B94], [@B113], [@B121], [@B125], [@B127], [@B134], [@B135]) and 11 studies indicated a decreasing trend with vitamin D supplementation ([@B69], [@B78], [@B80], [@B101], [@B108], [@B109], [@B115], [@B116], [@B118], [@B120], [@B124]). Seventeen of the 38 studies reported null findings or increased serum TG levels (Figure [4](#F4){ref-type="fig"}).

![Forest plot detailing standardized mean difference for the impact of vitamin D on serum triglyceride level.](fcvm-05-00087-g0004){#F4}

Thirty-eight studies included in the meta-analysis examined TC levels. The pooled effect size of vitamin D supplementation on TC was −0.15 ± 0.06 mmol/L (95% CI −0.26 to −0.04, *p* = 0.009, *I*^2^ = 57%; Figure [5](#F5){ref-type="fig"}). Vitamin D supplemented groups had lower TC levels at follow-up in seven individual studies ([@B82], [@B94], [@B107], [@B113], [@B118], [@B125], [@B134]), 18 studies found a non-significant trend for lower TC ([@B50], [@B79], [@B80], [@B92], [@B95], [@B101], [@B105], [@B108], [@B109], [@B115], [@B119]--[@B121], [@B126], [@B127], [@B130]--[@B132]) and 13 studies reported null effect or increased TC levels ([@B32], [@B62], [@B64], [@B69], [@B75], [@B76], [@B83], [@B84], [@B87], [@B91], [@B116], [@B124], [@B133]).

![Forest plot detailing standardized mean difference for the impact of vitamin D on serum total cholesterol level.](fcvm-05-00087-g0005){#F5}

Thirty-seven studies were included that reported LDL levels. The pooled effect size of vitamin D supplementation on LDL was −0.10 ± 0.05 mmol/L (95% CI −0.20 to −0.003, *p* = 0.04, *I*^2^ = 49%; Figure [6](#F6){ref-type="fig"}). Vitamin D supplementation was associated with reduced LDL levels in five individual trials ([@B92], [@B113], [@B126], [@B127], [@B132]), 17 studies reported a non-significant trend for decreased serum LDL ([@B50], [@B78]--[@B80], [@B94], [@B95], [@B105], [@B107]--[@B109], [@B115], [@B120], [@B121], [@B124], [@B125], [@B131], [@B134]), and 15 trials did not find any effect on LDL levels ([@B32], [@B62], [@B64], [@B69], [@B75], [@B83], [@B84], [@B87], [@B91], [@B101], [@B116], [@B117], [@B119], [@B133], [@B135]).

![Forest plot detailing standardized mean difference for the impact of vitamin D on serum LDL-cholesterol level.](fcvm-05-00087-g0006){#F6}

Serum HDL was a reported outcome for 39 studies. A significant effect of vitamin D supplementation on increased serum HDL was found with a pooled effect size of 0.09 ± 0.04 mmol/L \[95% CI 0.00 to 0.17, *p* = 0.05, *I*^2^ = 37%; Figure [7](#F7){ref-type="fig"}). Vitamin D supplementation significantly increased serum HDL in 6 individual studies ([@B32], [@B80], [@B92], [@B107], [@B113], [@B125]). Serum HDL cholesterol remained unchanged following vitamin D supplementation in 17 studies ([@B75], [@B95], [@B115], [@B119]--[@B121]) and an increase in serum HDL levels in 16 studies ([@B62], [@B64], [@B69], [@B78], [@B82]--[@B84], [@B91], [@B105], [@B108], [@B118], [@B126], [@B127], [@B130], [@B132], [@B134]) (Figure [7](#F7){ref-type="fig"}).
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### Vitamin D and PTH

Forty-five papers reported serum PTH levels as a primary or secondary endpoint. The pooled effect size of vitamin D on serum PTH levels was −0.66 ± 0.08 ng/L (95% CI −0.82 to −0.50, *p* \< 0.001, *I*^2^ = 87%) across all studies (Figure [8](#F8){ref-type="fig"}). Twenty eight individual studies reported a significant reduction in PTH levels with vitamin D supplementation ([@B32], [@B50], [@B65], [@B68], [@B70], [@B73]--[@B76], [@B82], [@B84], [@B87], [@B89], [@B92], [@B96]--[@B100], [@B102], [@B105], [@B117], [@B120], [@B125], [@B127], [@B131], [@B133], [@B136]), 15 reported a non-significant reduction in PTH ([@B60], [@B66], [@B67], [@B77], [@B90], [@B95], [@B104], [@B109], [@B116], [@B118], [@B119], [@B122], [@B129], [@B135], [@B138]) and two studies found no change or an increase in PTH levels ([@B110], [@B139]).

![Forest plot detailing standardized mean difference for the impact of vitamin D on serum PTH level.](fcvm-05-00087-g0008){#F8}

### Vitamin D and hs-CRP

Twenty eight studies reported hs-CRP concentration as an outcome. The pooled effect size (standardized mean difference) of vitamin D supplementation on serum hs-CRP was −0.20 ± 0.07 mg/L (95% CI −0.34 to −0.06, *p* = 0.006, *I*^2^ = 73%) across all studies (Figure [9](#F9){ref-type="fig"}). Eight individual studies reported a significant reduction in serum hs-CRP following vitamin D supplementation ([@B64], [@B66], [@B69], [@B83], [@B92], [@B112], [@B130], [@B133]), 13 indicated a non-significant reduction in hs-CRP ([@B65], [@B71], [@B72], [@B78], [@B80], [@B82], [@B86], [@B87], [@B116], [@B120], [@B126], [@B131], [@B137]), and seven found either a null effect ([@B85]) or an increase in hs-CRP in the vitamin D supplemented group ([@B106], [@B115], [@B119], [@B122], [@B127], [@B135]).

![Forest plot detailing standardized mean difference for the impact of vitamin D on serum high sensitivity CRP level.](fcvm-05-00087-g0009){#F9}

### Vitamin D and peak wave velocity

Eleven papers reported PWV as a primary or secondary outcome. Overall, there was no significant effect of vitamin D supplementation on PWV. The pooled effect size of vitamin D on PWV was −0.20 ± 0.13 m/s \[95% CI −0.46 to 0.06, *p* = 0.13, *I*^2^ = 72%) across all studies (Figure [10](#F10){ref-type="fig"}). Four individual studies reported a significant reduction in PWV in the group supplemented with vitamin D ([@B77], [@B82], [@B114], [@B128]), two studies found a non-significant trend for reduction in PWV ([@B88], [@B131]), and five trials did not find any significant effect of vitamin D on PWV ([@B33], [@B84], [@B85], [@B100], [@B106]).

![Forest plot detailing standardized mean difference for the impact of vitamin D on peak wave velocity.](fcvm-05-00087-g0010){#F10}

### Vitamin D and augmentation index

Ten studies reported AI as an outcome (Figure [11](#F11){ref-type="fig"}). Overall, vitamin D supplementation did not have an effect on AI. The pooled estimate (standardized mean difference) of the effect of vitamin D administration on AI was −0.09 ± 0.14% (95% CI −0.37 to 0.20%, *p* = 0.52, *I*^2^ = 74%).

![Forest plot detailing standardized mean difference for the impact of vitamin D on augmentation index.](fcvm-05-00087-g0011){#F11}

Two studies reported a significant decrease in AI ([@B69], [@B128]), two studies reported a significant increase in AI ([@B85], [@B106]), and six trials did not find any influence of vitamin D supplementation on AI ([@B33], [@B84], [@B86], [@B100], [@B103], [@B131]).

Sensitivity analysis
--------------------

Using leave-one-out sensitivity analysis, the effect size of vitamin D remained significant for blood pressure, lipid profile, serum PTH, and serum hs-CRP, confirming that difference between treatment groups is not due to the effect of any single study.

We then removed more than one study based on a number of possible outliers and repeated meta-analysis. For serum PTH, three studies were removed ([@B89], [@B98], [@B127]) and vitamin D supplementation still significantly lowered serum PTH (−0.53 ± 0.06 ng/L, 95% CI −0.65 to −0.41, *p* \< 0.001). For serum hs-CRP, two studies were removed ([@B64], [@B92]) and we found significant reduction in serum hs-CRP following vitamin D supplementation (−0.12 ± 0.06 mg/L, 95% CI −0.24 to −0.003, *p* = 0.04). Three studies were removed as outliers for serum TC ([@B32], [@B76], [@B134]) and there was still a significant lowering effect of vitamin D supplementation on serum TC (−0.14 ± 0.04 mmol/L, 95% CI −0.22 to −0.06, *p* \< 0.001). There was one outlier for serum LDL ([@B92]); after removing this study, serum LDL decreased following vitamin D supplementation by −0.08 ± 0.05 mmol/L (95% CI −0.18 to 0.01, *p* = 0.07). Salehpour ([@B32]) study was removed as an outlier for serum HDL and the overall vitamin D effect size was 0.06 ± 0.04 mmol/L (95% CI −0.01 to 0.12, *p* = 0.12). For systolic BP, three studies were removed ([@B61], [@B76], [@B81]) and there was a non-significant decreased trend in systolic BP following vitamin D supplementation (−0.04 ± 0.03 mmHg, 95% CI −0.09 to 0.02, *p* = 0.2). We did not identify any outliers for diastolic BP, PWV, AI, and serum TG.

Publication bias
----------------

Visual inspection of funnel plot symmetry suggested potential publication bias for the comparison of systolic and diastolic BP, PTH, PWV, TC, HDL, and hs-CRP between vitamin D-administered and placebo groups, though funnel plots for AI, TG, and LDL looked symmetric (Figures [S1](#SM3){ref-type="supplementary-material"}--[S10](#SM3){ref-type="supplementary-material"}). Egger\'s linear regressions did not indicate publication bias. After adjusting the effect size using the Trim and Fill method for potential publication bias, except for PWV, the effect size of vitamin D on lowering CVD risk parameters increased (BP, hs-CRP, PTH, AI, TC, LDL) or remained unchanged (TG, HDL) (Table [S2](#SM2){ref-type="supplementary-material"}).

Sub-group analysis
------------------

We investigated the effect of dose, achieved mean serum 25(OH)D, length of intervention, obesity, vitamin D deficiency, co-administration of calcium supplementation and age.

### Achieved serum 25(OH)D concentrations at the end of the trial

We investigated the effect of achieved serum 25(OH)D as high vs. low based on median levels (Table [2](#T2){ref-type="table"}). Serum 25(OH)D concentrations ≥86 nmol/L resulted in a significantly higher reduction in systolic (−0.15 ± 0.06 vs. −0.04 ± 0.04 mmHg, *p* = 0.05), diastolic BP (−0.12 ± 0.05 vs. −0.01 ± 0.04 mmHg, *p* = 0.04), PWV (−0.28 ± 0.16 vs. −0.004 ± 0.29 m/s, *p* = 0.08), and hs-CRP (−0.23 ± 0.09 vs. −0.11 ± 0.16 md/L, *p* = 0.07). AI, for which there was no significant effect overall, was found to be significantly lower among participants with serum 25(OH)D concentrations ≥86 nmol/L (−0.16 ± 0.2% vs. −0.005 ± 0.2%, *p* = 0.05). PTH and lipid changes did not significantly differ based on achieved serum 25(OH)D concentration.

###### 

Meta-analysis and subgroup analysis of primary and secondary outcomes.

  **Subgroup analysis**                                    **No. of study**   **No. of subjects**   **Standardized Mean difference (95% CI)**   ***P value***                    **Between groups *P value[^\*^](#TN4){ref-type="table-fn"}***   
  -------------------------------------------------------- ------------------ --------------------- ------------------------------------------- -------------------------------- --------------------------------------------------------------- ----------------------------------------
  **SERUM 25(OH)D LEVEL AT FOLLOW-UP**                                                                                                                                                                                                           
  **Systolic blood pressure**                                                                                                                                                                                                                    
  \<86 nmol/L                                              17                 1,008                 993                                         −0.04 ± 0.04 (−0.12 to 0.05)     0.44                                                            0.05[^\*^](#TN4){ref-type="table-fn"}
  ≥86 nmol/L                                               22                 1,390                 1,414                                       −0.15 ± 0.06 (−0.29 to −0.01)    0.04                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  \<86 nmol/L                                              17                 1,008                 993                                         −0.01 ± 0.04 (−0.10 to 0.07)     0.75                                                            0.04[^\*^](#TN4){ref-type="table-fn"}
  ≥86 nmol/L                                               22                 1,390                 1,414                                       −0.12 ± 0.05 (−0.21 to −0.02)    0.01                                                            
  **Augmentation Index**                                                                                                                                                                                                                         
  \<86 nmol/L                                              5                  149                   145                                         −0.005 ± 0.2 (−0.41 to 0.39)     0.98                                                            0.05[^\*^](#TN4){ref-type="table-fn"}
  ≥86 nmol/L                                               5                  282                   281                                         −0.16 ± 0.2 (−0.55 to 0.23)      0.42                                                            
  **Peak Wave Velocity**                                                                                                                                                                                                                         
  \<86 nmol/L                                              4                  179                   181                                         −0.004 ± 0.29 (−0.56 to 0.56)    0.98                                                            0.08
  ≥86 nmol/L                                               7                  304                   300                                         −0.28 ± 0.16 (−0.61 to 0.04)     0.08                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  \<86 nmol/L                                              8                  355                   352                                         −0.11 ± 0.16 (−0.42 to 0.21)     0.50                                                            0.07
  ≥86 nmol/L                                               20                 1,311                 1,216                                       −0.23 ± 0.09 (−0.40 to −0.07)    0.006                                                           
  **Serum PTH**                                                                                                                                                                                                                                  
  \<86 nmol/L                                              25                 1,387                 1,388                                       −0.66 ± 0.11 (−0.88 to −0.44)    \<0.001                                                         0.36
  ≥86 nmol/L                                               21                 1,429                 1,332                                       −0.65 ± 0.13 (−0.90 to −0.40)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  \<86 nmol/L                                              23                 981                   971                                         −0.18 ± 0.09 (−0.35 to −0.01)    0.03                                                            0.22
  ≥86 nmol/L                                               15                 794                   801                                         −0.10 ± 0.05 (−0.20 to −0.004)   0.04                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  \<86 nmol/L                                              21                 854                   847                                         −0.16 ± 0.08 (−0.32 to 0.008)    0.06                                                            0.18
  ≥86 nmol/L                                               17                 992                   1,000                                       −0.08 ± 0.09 (−0.24 to 0.09)     0.38                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  \<86 nmol/L                                              21                 943                   936                                         0.10 ± 0.07 (−0.3 to 0.23)       0.13                                                            0.45
  ≥86 nmol/L                                               18                 1,024                 1,032                                       0.07 ± 0.05 (−0.04 to 0.17)      0.24                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  \<86 nmol/L                                              20                 821                   809                                         −0.11 ± 0.06 (−0.22 to 0.002)    0.054                                                           0.35
  ≥86 nmol/L                                               17                 1,002                 1,011                                       −0.09 ± 0.08 (−0.25 to 0.08)     0.29                                                            
  **VITAMIN D SUPPLEMENTATION DOSE**                                                                                                                                                                                                             
  **Systolic blood pressure**                                                                                                                                                                                                                    
  \<4,000 IU/d                                             25                 1,672                 1,664                                       −0.01 ± 0.03 (−0.08 to 0.06)     0.77                                                            0.001[^\*^](#TN4){ref-type="table-fn"}
  ≥4,000 IU/d                                              14                 748                   756                                         −0.31 ± 0.12 (−0.55 to −0.07)    0.01                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  \<4,000 IU/d                                             25                 1,672                 1,664                                       −0.03 ± 0.03 (−0.10 to 0.04)     0.43                                                            0.05[^\*^](#TN4){ref-type="table-fn"}
  ≥4,000 IU/d                                              14                 748                   756                                         −0.17 ± 0.09 (−0.35 to 0.01)     0.06                                                            
  **Augmentation index**                                                                                                                                                                                                                         
  \<4,000 IU/d                                             8                  315                   307                                         0.007 ± 0.12 (−0.23 to 0.25)     0.95                                                            0.07
  ≥4,000 IU/d                                              2                  116                   119                                         −0.46 ± 0.31 (−1.07 to 0.15)     0.13                                                            
  **Peak Wave Velocity**                                                                                                                                                                                                                         
  \<4,000 IU/d                                             7                  319                   315                                         −0.13 ± 0.14 (−0.41 to 0.15)     0.38                                                            0.29
  ≥4,000 IU/d                                              4                  164                   166                                         −0.32 ± 0.29 (−0.88 to 0.24)     0.27                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  \<4,000 IU/d                                             20                 1,376                 1,282                                       −0.16 ± 0.1 (−0.34 to 0.02)      0.07                                                            0.05[^\*^](#TN4){ref-type="table-fn"}
  ≥4,000 IU/d                                              8                  290                   286                                         −0.28 ± 0.1 (−0.48 to −0.08)     0.006                                                           
  **Serum PTH**                                                                                                                                                                                                                                  
  \<4,000 IU/d                                             31                 2,134                 2,041                                       −0.61 ± 0.1 (−0.80 to −0.42)     \<0.001                                                         0.21
  ≥4,000 IU/d                                              15                 682                   679                                         −0.77 ± 0.17 (−1.11 to −0.43)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  \<4,000 IU/d                                             24                 1,318                 1,308                                       −0.13 ± 0.05 (−0.24 to −0.03)    0.01                                                            0.43
  ≥4,000 IU/d                                              14                 457                   464                                         −0.16 ± 0.13 (−0.42 to 0.11)     0.25                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  \<4,000 IU/d                                             25                 1,402                 1,393                                       −0.14 ± 0.07 (−0.29 to 0.003)    0.054                                                           0.28
  ≥4,000 IU/d                                              13                 444                   454                                         −0.06 ± 0.1 (−0.26 to 0.13)      0.51                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  \<4,000 IU/d                                             26                 1,523                 1,514                                       0.11 ± 0.06 (0.003 to 0.22)      0.04                                                            0.13
  ≥4,000 IU/d                                              13                 444                   454                                         0.03 ± 0.07 (−0.10 to 0.16)      0.67                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  \<4,000 IU/d                                             25                 1,401                 1,387                                       −0.13 ± 0.07 (−0.25 to 0.003)    0.055                                                           0.14
  ≥4,000 IU/d                                              12                 422                   433                                         −0.04 ± 0.07 (−0.18 to 0.09)     0.54                                                            
  **DURATION OF INTERVENTION**                                                                                                                                                                                                                   
  **Systolic blood pressure**                                                                                                                                                                                                                    
  \<6 months                                               16                 750                   743                                         −0.22 ± 0.1 (−0.42 to −0.02)     0.03                                                            0.04[^\*^](#TN4){ref-type="table-fn"}
  ≥6 months                                                23                 1,648                 1,664                                       −0.02 ± 0.03 (−0.09 to 0.05)     0.58                                                            
  **Diastolic Blood Pressure**                                                                                                                                                                                                                   
  \<6 months                                               16                 750                   743                                         −0.15 ± 0.07 (−0.29 to −0.01)    0.03                                                            0.02[^\*^](#TN4){ref-type="table-fn"}
  ≥6 months                                                23                 1,648                 1,664                                       −0.03 ± 0.03 (−0.10 to 0.04)     0.35                                                            
  **Augmentation Index**                                                                                                                                                                                                                         
  \<6 months                                               4                  192                   185                                         0.08 ± 0.11 (−0.14 to 0.30)      0.46                                                            0.11
  ≥6 months                                                6                  239                   241                                         −0.20 ± 0.21 (−0.61 to 0.21)     0.34                                                            
  **Peak Wave Velocity**                                                                                                                                                                                                                         
  \<6 months                                               6                  287                   282                                         −0.23 ± 0.16 (−0.54 to 0.08)     0.15                                                            0.25
  ≥6 months                                                5                  196                   199                                         −0.12 ± 0.26 (−0.63 to 0.38)     0.63                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  \<6 months                                               7                  336                   331                                         −0.32 ± 0.19 (−0.70 to 0.05)     0.09                                                            0.24
  ≥6 months                                                21                 1,330                 1,237                                       −0.17 ± 0.08 (−0.32 to −0.01)    0.03                                                            
  **Serum PTH**                                                                                                                                                                                                                                  
  \<6 months                                               11                 402                   414                                         −0.70 ± 0.08 (−0.85 to −0.54)    \<0.001                                                         0.41
  ≥6 months                                                35                 2,414                 2,306                                       −0.66 ± 0.1 (−0.86 to −0.46)     \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  \<6 months                                               15                 619                   628                                         −0.25 ± 0.12 (−0.48 to −0.02)    0.03                                                            0.07
  ≥6 months                                                23                 1,156                 1,144                                       −0.10 ± 0.06 (−0.20 to 0.01)     0.07                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  \<6 months                                               14                 505                   514                                         −0.31 ± 0.09 (−0.48 to −0.13)    0.001                                                           0.006[^\*^](#TN4){ref-type="table-fn"}
  ≥6 months                                                24                 1,341                 1,333                                       −0.02 ± 0.07 (−0.16 to 0.12)     0.82                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  \<6 months                                               15                 619                   628                                         0.19 ± 0.09 (0.008 to 0.37)      0.04                                                            0.04[^\*^](#TN4){ref-type="table-fn"}
  ≥6 months                                                24                 1,348                 1,340                                       0.03 ± 0.04 (−0.05 to 0.11)      0.44                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  \<6 months                                               13                 472                   476                                         −0.14 ± 0.09 (−0.32 to 0.03)     0.11                                                            0.18
  ≥6 months                                                24                 1,351                 1,344                                       −0.08 ± 0.06 (−0.20 to 0.04)     0.18                                                            
  **OBESITY (BMI** ≥ **30 KG/M**^2^**)**                                                                                                                                                                                                         
  **Systolic blood pressure**                                                                                                                                                                                                                    
  Obese                                                    19                 999                   999                                         −0.19 ± 0.09 (−0.37 to −0.01)    0.03                                                            0.02[^\*^](#TN4){ref-type="table-fn"}
  Non-obese                                                20                 1,298                 1,408                                       −0.05 ± 0.04 (−0.12 to 0.03)     0.20                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  Obese                                                    19                 999                   999                                         −0.12 ± 0.06 (−0.23 to −0.01)    0.04                                                            0.08
  Non-obese                                                20                 1,298                 1,408                                       −0.04 ± 0.04 (−0.12 to 0.04)     0.31                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  Obese                                                    11                 635                   535                                         −0.18 ± 0.12 (−0.43 to 0.06)     0.13                                                            0.45
  Non-obese                                                17                 1,031                 1,033                                       −0.21 ± 0.09 (−0.39 to −0.03)    0.02                                                            
  **Serum PTH**                                                                                                                                                                                                                                  
  Obese                                                    15                 842                   741                                         −0.47 ± 0.06 (−0.58 to −0.35)    \<0.001                                                         0.22
  Non-obese                                                31                 1,974                 1,979                                       −0.72 ± 0.12 (−0.94 to −0.49)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  Obese                                                    19                 781                   792                                         −0.10 ± 0.08 (−0.26 to 0.05)     0.19                                                            0.17
  Non-obese                                                19                 994                   980                                         −0.19 ± 0.08 (−0.34 to −0.03)    0.02                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  Obese                                                    19                 1,013                 1,028                                       −0.06 ± 0.07 (−0.21 to 0.08)     0.41                                                            0.10
  Non-obese                                                19                 833                   819                                         −0.18 ± 0.09 (−0.36 to 0.006)    0.059                                                           
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  Obese                                                    18                 771                   786                                         0.14 ± 0.07 (−0.006 to 0.28)     0.06                                                            0.23
  Non-obese                                                21                 1,196                 1,182                                       0.04 ± 0.05 (−0.06 to 0.14)      0.43                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  Obese                                                    16                 716                   727                                         −0.04 ± 0.05 (−0.14 to 0.07)     0.47                                                            0.20
  Non-obese                                                21                 1,107                 1,093                                       −0.14 ± 0.07 (−0.29 to 0.00)     0.05                                                            
  **VITAMIN D DEFICIENCY AT BASELINE (**\<**50 NMOL/L)**                                                                                                                                                                                         
  **Systolic blood pressure**                                                                                                                                                                                                                    
  \<50 nmol/L                                              26                 1,345                 1,363                                       −0.12 ± 0.06 (−0.25 to 0.01)     0.06                                                            0.16
  ≥50 nmol/L                                               13                 1,044                 1,044                                       −0.06 ± 0.06 (−0.18 to 0.05)     0.27                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  \<50 nmol/L                                              26                 1,345                 1,363                                       −0.06 ± 0.05 (−0.16 to 0.03)     0.21                                                            0.18
  ≥50 nmol/L                                               13                 1,044                 1,044                                       −0.08 ± 0.04 (−0.17 to 0.006)    0.07                                                            
  **Augmentation Index**                                                                                                                                                                                                                         
  \<50 nmol/L                                              5                  149                   145                                         −0.005 ± 0.2 (−0.41 to 0.39)     0.97                                                            0.10
  ≥50 nmol/L                                               5                  282                   281                                         −0.16 ± 0.2 (−0.55 to 0.23)      0.42                                                            
  **Peak Wave Velocity**                                                                                                                                                                                                                         
  \<50 nmol/L                                              8                  272                   267                                         −0.19 ± 0.15 (−0.49 to 0.11)     0.22                                                            0.42
  ≥50 nmol/L                                               3                  211                   214                                         −0.22 ± 0.30 (−0.81 to 0.38)     0.47                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  \<50 nmol/L                                              18                 738                   747                                         −0.20 ± 0.11 (−0.42 to 0.02)     0.07                                                            0.45
  ≥50 nmol/L                                               10                 928                   821                                         −0.20 ± 0.09 (−0.38 to −0.007)   0.04                                                            
  **Serum PTH**                                                                                                                                                                                                                                  
  \<50 nmol/L                                              29                 1,464                 1,471                                       −0.81 ± 0.12 (−1.05 to −0.58)    \<0.001                                                         0.01[^\*^](#TN4){ref-type="table-fn"}
  ≥50 nmol/L                                               17                 1,352                 1,249                                       −0.43 ± 0.10 (−0.63 to −0.22)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  \<50 nmol/L                                              28                 1,069                 1,071                                       −0.12 ± 0.07 (−0.26 to 0.02)     0.09                                                            0.31
  ≥50 nmol/L                                               10                 706                   701                                         −0.20 ± 0.09 (−0.37 to −0.03)    0.02                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  \<50 nmol/L                                              28                 1,140                 1,146                                       −0.13 ± 0.07 (−0.26 to 0.006)    0.06                                                            0.46
  ≥50 nmol/L                                               10                 706                   701                                         −0.10 ± 0.12 (−0.34 to 0.14)     0.41                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  \<50 nmol/L                                              29                 1,261                 1,267                                       0.05 ± 0.05 (−0.04 to 0.15)      0.31                                                            0.09
  ≥50 nmol/L                                               10                 706                   701                                         0.17 ± 0.08 (0.006 to 0.33)      0.04                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  \<50 nmol/L                                              28                 1,150                 1,157                                       −0.05 ± 0.05 (−0.14 to 0.05)     0.32                                                            0.05[^\*^](#TN4){ref-type="table-fn"}
  ≥ 50 nmol/L                                              9                  673                   663                                         −0.24 ± 0.11 (−0.46 to −0.02)    0.03                                                            
  **CALCIUM CO-SUPPLEMENTATION**                                                                                                                                                                                                                 
  **Systolic blood pressure**                                                                                                                                                                                                                    
  Yes                                                      7                  512                   514                                         −0.19 ± 0.2 (−0.58 to 0.19)      0.33                                                            0.07
  No                                                       32                 1,886                 1,893                                       −0.07 ± 0.03 (−0.13 to −0.004)   0.04                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  Yes                                                      7                  512                   514                                         −0.12 ± 0.12 (−0.35 to 0.12)     0.34                                                            0.33
  No                                                       32                 1,886                 1,893                                       −0.06 ± 0.03 (−0.13 to 0.003)    0.06                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  Yes                                                      8                  627                   530                                         −0.12 ± 0.13 (−0.38 to 0.13)     0.33                                                            0.19
  No                                                       20                 1,039                 1,038                                       −0.24 ± 0.09 (−0.42 to −0.06)    0.01                                                            
  **Serum PTH**                                                                                                                                                                                                                                  
  Yes                                                      17                 1,369                 1,278                                       −0.58 ± 0.14 (−0.85 to −0.31)    \<0.001                                                         0.21
  No                                                       29                 1,447                 1,442                                       −0.71 ± 0.11 (−0.93 to −0.50)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  Yes                                                      8                  383                   392                                         −0.16 ± 0.10 (−0.37 to 0.04)     0.13                                                            0.41
  No                                                       30                 1,392                 1,380                                       −0.14 ± 0.07 (−0.27 to −0.01)    0.03                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  Yes                                                      9                  436                   438                                         −0.18 ± 0.13 (−0.43 to 0.07)     0.16                                                            0.11
  No                                                       29                 1,410                 1,409                                       −0.10 ± 0.07 (−0.23 to 0.03)     0.14                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  Yes                                                      10                 468                   470                                         0.07 ± 0.09 (−0.11 to 0.26)      0.42                                                            0.39
  No                                                       29                 1,499                 1,498                                       0.09 ± 0.05 (−0.009 to 0.18)     0.07                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  Yes                                                      9                  435                   432                                         −0.11 ± 0.1 (−0.31 to 0.09)      0.28                                                            0.38
  No                                                       28                 1,388                 1,388                                       −0.10 ± 0.06 (−0.21 to 0.02)     0.09                                                            
  **PARTICIPANT\'S AGE (55 YEARS)**                                                                                                                                                                                                              
  **Systolic blood pressure**                                                                                                                                                                                                                    
  \<55 years                                               21                 1,264                 1,270                                       −0.14 ± 0.07 (−0.29 to −0.003)   0.04                                                            0.07
  ≥55 years                                                18                 1,134                 1,137                                       −0.05 ± 0.05 (−0.15 to 0.05)     0.33                                                            
  **Diastolic blood pressure**                                                                                                                                                                                                                   
  \<55 years                                               21                 1,264                 1,270                                       −0.08 ± 0.06 (−0.19 to 0.04)     0.17                                                            0.21
  ≥55 years                                                18                 1,134                 1,137                                       −0.07 ± 0.04 (−0.15 to 0.01)     0.08                                                            
  **Augmentation Index**                                                                                                                                                                                                                         
  \<55 years                                               4                  122                   115                                         0.04 ± 0.13 (−0.22 to 0.29)      0.76                                                            0.31
  ≥55 years                                                6                  309                   311                                         −0.15 ± 0.21 (−0.56 to 0.27)     0.48                                                            
  **Peak Wave Velocity**                                                                                                                                                                                                                         
  \<55 years                                               6                  217                   212                                         −0.21 ± 0.19 (−0.59 to 0.16)     0.27                                                            0.45
  ≥55 years                                                5                  266                   269                                         −0.18 ± 0.21 (−0.59 to 0.24)     0.40                                                            
  **Serum C-Reactive Protein**                                                                                                                                                                                                                   
  \<55 years                                               14                 795                   587                                         −0.14 ± 0.06 (−0.25 to −0.02)    0.01                                                            0.48
  ≥55 years                                                14                 871                   881                                         −0.22 ± 0.13 (−0.48 to 0.04)     0.09                                                            
  **Serum PTH**                                                                                                                                                                                                                                  
  \<55 years                                               20                 1,063                 966                                         −0.65 ± 0.1 (−0.85 to −0.46)     \<0.001                                                         0.45
  ≥55 years                                                26                 1,753                 1,754                                       −0.65 ± 0.12 (−0.90 to −0.41)    \<0.001                                                         
  **Total Cholesterol (TC)**                                                                                                                                                                                                                     
  \<55 years                                               22                 801                   808                                         −0.17 ± 0.09 (−0.34 to 0.007)    0.06                                                            0.34
  ≥55 years                                                16                 974                   964                                         −0.12 ± 0.07 (−0.25 to 0.008)    0.06                                                            
  **Triglyceride (TG)**                                                                                                                                                                                                                          
  \<55 years                                               23                 862                   876                                         −0.14 ± 0.08 (−0.30 to 0.014)    0.07                                                            0.37
  ≥55 years                                                15                 984                   971                                         −0.08 ± 0.09 (−0.26 to 0.09)     0.09                                                            
  **HDL Cholesterol (HDL)**                                                                                                                                                                                                                      
  \<55 years                                               23                 951                   965                                         0.08 ± 0.06 (−0.04 to 0.19)      0.19                                                            0.26
  ≥55 years                                                16                 1,016                 1,003                                       0.10 ± 0.06 (−0.03 to 0.22)      0.14                                                            
  **LDL Cholesterol (LDL)**                                                                                                                                                                                                                      
  \<55 years                                               21                 807                   817                                         −0.04 ± 0.06 (−0.16 to 0.07)     0.47                                                            0.10
  ≥55 years                                                16                 1,016                 1,003                                       −0.16 ± 0.08 (−0.31 to −0.008)   0.03                                                            

*P-value represents within group comparison, subgroup analysis was not done for 2HPG and obesity (one study in obese subgroup), Independent T-test for between groups comparison*,

*p-values adjusted by Bonferroni correction*.

### Vitamin D supplementation dose

We investigated dose effect on outcomes by comparing trials in which subjects received ≥4,000 IU/d of vitamin D to those in which subjects received \<4,000 IU/d (Table [2](#T2){ref-type="table"}). Trials with vitamin D doses ≥4,000 IU/d had significantly greater reduction in systolic (−0.31 ± 0.12 vs. −0.01 ± 0.03 mmHg, *p* = 0.001), diastolic BP (−0.17 ± 0.09 vs. −0.03 ± 0.03 mmHg, *p* = 0.05), and hs-CRP (−0.28 ± 0.1 vs. −0.16 ± 0.1 mg/L, *p* = 0.05). AI was significantly lowered in trials with vitamin D doses ≥4,000 IU/d (−0.46 ± 0.31% vs. 0.007 ± 0.12%, *p* = 0.07).

### Duration of intervention

To investigate whether the length of the trial influenced the effect of vitamin D supplementation on outcomes we investigated trials that supplemented for ≥6 months in comparison with those \<6 months in duration (Table [2](#T2){ref-type="table"}). In trials that assessed vitamin D supplementation for \<6 months there was a significantly greater decrease in systolic (−0.22 ± 0.1 vs. −0.02 ±0.03 mmHg, *p* = 0.04), diastolic BP (−0.15 ± 0.07 vs. −0.03 ± 0.03 mmHg, *p* = 0.02), and TG (−0.31 ± 0.09 vs. −0.02 ± 0.07 mmol/L), and a greater increase in HDL (0.19 ± 0.09 vs. 0.03 ± 0.04 mmol/L, *p* = 0.04).

### Obesity

We investigated whether outcomes differed between trials that enrolled an obese (BMI ≥ 30 kg/m^2^) population vs. non-obese (Table [2](#T2){ref-type="table"}). In trials with obese subjects there was a significantly greater reduction in systolic (−0.19 ± 0.09 vs. −0.05 ± 0.04 mmHg, *p* = 0.02) and diastolic BP (−0.12 ± 0.06 vs. −0.04 ± 0.04 mmHg, *p* = 0.08). There was no significant difference in other outcomes based on obesity.

### Vitamin D deficiency at baseline

We investigated whether the effect of vitamin D on outcomes was dependent on vitamin D deficiency at baseline by comparing trials vitamin D deficient subjects at baseline \[serum 25(OH)D \<50 nmol/L\] vs. vitamin D sufficient subjects (Table [2](#T2){ref-type="table"}). Vitamin D supplementation in trials with participants who were vitamin D deficient had a significantly greater reduction in PTH (−0.81 ± 0.12 vs. −0.43 ± 0.1 ng/L, *p* = 0.01), LDL (−0.24 ± 0.11 vs. −0.05 ± 0.05 mmol/L, *p* = 0.05) and AI (−0.16 ± 0.2% vs. −0.005 ± 0.2%, *p* = 0.10), and a greater increase in HDL (0.17 ± 0.08 vs. 0.05 ± 0.05 mmol/L, *p* = 0.09) in comparison with vitamin D sufficient participants.

### Calcium co-administration

We investigated whether calcium co-administration influenced outcomes by comparing those trials with those that supplemented with vitamin D alone (Table [2](#T2){ref-type="table"}). Participants supplemented with both vitamin D and calcium had a significantly greater reduction in systolic BP (−0.19 ± 0.2 vs. −0.07 ±0.03 mmHg, *p* = 0.07) and TG levels (−0.18 ± 0.13 vs. −0.10 ±0.07 mmol/L, *p* = 0.11), compared with those who received vitamin D alone. There was no difference among the remaining parameters.

### Effect of participants\' age

Age itself is a risk factor for CVD and thus we compared trials that enrolled populations ≥55 y vs. \<55 y. Vitamin D supplementation in trials with populations \<55 y had significantly greater reduction in systolic BP (−0.14 ± 0.07 vs.−0.05 ± 0.05 mmHg, *p* = 0.07). There was no significant difference in other outcomes based on participant age grouping.

Discussion {#s4}
==========

As the leading cause of death and disability worldwide, cardiovascular disease (CVD) is a major public health burden ([@B140]). Much effort has been devoted to identifying modifiable risk factors to prevent CVD. Vitamins may have a role in the prevention and treatment of CVD. Antioxidant vitamins such as vitamin C, vitamin E, folic acid and vitamin B6 might decrease the rate of oxidative stress, a key component of atherosclerosis and CVD ([@B14]). Vitamin D and folic acid can inhibit inflammation with their anti-atherogenic effects. Vitamin E can inhibit platelet aggregation and B vitamins might have anti-thrombotic activity by lowering serum homocysteine levels ([@B14], [@B141], [@B142]). Among these, vitamin D, with its deficiency highly prevalent worldwide and having many pleiotropic effects, has been associated with CVD prevention in different community settings. Vitamin D deficiency impairs vascular function and is strongly associated with the heightened risks of various cardiovascular diseases such as hypertension, metabolic syndrome, heart failure, and stroke ([@B3], [@B24]).

Evidence suggests that vitamin D exerts beneficial cardiovascular effects through many pathways. Improved vitamin D status reduces RAAS activity and lowers blood pressure, it has anti-inflammatory, anti-proliferative, anti-hypertrophic, anti-fibrotic and anti-thrombotic impacts as well ([@B111]). Following vitamin D supplementation, suppression of renin production and downregulation of RAAS directly impacts myocardium and vasculature through modulating hypertrophic stimuli ([@B143]). Vitamin D inhibits the proliferation of vascular smooth muscle cells through influx of calcium into the cells, thus preserving endothelial function ([@B144]). Antihypertensive benefits of vitamin D include suppression of RAAS, an anti-proteinuric effect, a direct effect on endothelial cells and calcium metabolism as well as preventing secondary hyperparathyroidism ([@B145], [@B146]). Vitamin D may have both direct and indirect impacts on modifying lipid profiles. Vitamin D supplementation might decrease serum levels of triglyceride via increasing the activity of lipoprotein lipase in adipose tissue ([@B147]). Also, through improving calcium absorption, vitamin D might reduce fatty acid absorption via the formation of insoluble calcium-fatty acid complexes in the gut leading to decreased LDL cholesterol levels ([@B148]). Yet, despite these observations, evidence linking corrections to vitamin D status with improved cardiometabolic parameters is somewhat inconclusive ([@B24], [@B43], [@B149]).

Considering the alternate postulation, vitamin D deficiency might be a consequence of chronic conditions such as inflammation. There is a bacterial pathogenesis theory explains that intracellular bacteria commonly seen in chronic inflammation might invade different nucleated cells and affect vitamin D metabolism and its endocrine function resulting in low vitamin D status. This occurs concurrent to increased production of 1,25(OH)2D which is required for upregulating vitamin D receptors to transcribes more adenosine monophosphate. And more 25(OH)D should be metabolized in this process leading to low vitamin D status ([@B150], [@B151]). In another study conducted on the patients recovering from knee arthroplasty, there was a significant reduction in serum 25(OH)D levels during the process of systemic inflammatory response in these patients after surgery ([@B152]). Sattar et al. ([@B153]) also mentioned that vitamin D is an acute phase reactant and declines with the increase in inflammatory cytokine in different chronic conditions. Several mechanisms including decreased vitamin D carrier proteins, increased conversion of 25(OH)D to 1,25(OH)2D and hemodilution could be responsible for this reduction ([@B154], [@B155]). However for CVD, using Hill\'s criteria for causality, Weyland found that all relevant Hill criteria are satisfied suggesting low 25(OH)D level is an independent risk factor for CVD ([@B156]).

To better understand this incongruence, we analyzed 81 studies that evaluated the effect of vitamin D supplementation on various cardiometabolic risk parameters, including blood pressure, serum PTH, hs-CRP, lipid profile, and arterial PWV and AI. Unlike many previous studies, we imposed several strict inclusion criteria to select only well-designed trials. Overall, vitamin D supplementation was found to improve cardiovascular risk factors. Specifically, vitamin D supplementation, with doses above 4,000 IU/d and increased serum 25(OH)D concentrations ≥86 nmol/L decreased systolic and diastolic blood pressure, serum PTH, serum hs-CRP and improved lipid profiles (total cholesterol, triglyceride, HDL and LDL). Markers of arterial stiffness (PWV and AI) may also improve with vitamin D supplementation.

Subgroup analyses revealed that the co-administration of calcium with vitamin D led to greater reductions in blood pressure. The combination of calcium with vitamin D has been suggested to improve blood pressure by facilitating calcium absorption into the blood stream and optimizing serum calcium and PTH levels ([@B157], [@B158]). Although the greatest benefits of vitamin D supplementation can be achieved in vitamin D deficient populations, such that we observed as the lowering impact of vitamin D on serum PTH. Remarkably, we also found notable improvements in lipid profile in participants considered vitamin D sufficient prior to intervention. Further, individuals who were obese at baseline had a greater reduction in blood pressure, likely due to the higher percentage of obese individuals that are pre-hypertensive or hypertensive ([@B159]) and the higher daily doses of vitamin D provided to obese participants ([@B61], [@B76], [@B81]).

The results of our study compare closely with those from a number of recent meta-analyses. Jafari et al. ([@B93]), for instance, found significant reductions in the serum total cholesterol, triglyceride, and LDL levels of type 2 diabetics following vitamin D supplementation. Studying heterogeneous populations that consisted of healthy individuals, pregnant women, bedridden elderly people and those with different diseases (e.g., diabetes, heart failure, PCOS, and insulin resistant condition), both Chen et al. ([@B160]) and Rodriguez et al. ([@B161]) found that vitamin D supplementation significantly decreased inflammatory markers (i.e., hs-CRP). Chen et al. ([@B160]) additionally concluded that vitamin D supplementation led to a significantly greater reduction among those with baseline hs-CRP levels ≥5 mg/l. This is in line with increased hs-CRP levels in diabetic patients ([@B64], [@B69], [@B92]). Diabetes usually results in higher levels of hs-CRP and lower levels of 25(OH)D concentrations suggesting a larger effect size in subjects with this condition. Moreover, Wu et al. ([@B162]) and Witham et al. ([@B163]) found a significant modest reduction in blood pressure following vitamin D supplementation. Vitamin D supplementation may affect arterial stiffness and vascular aging through decreased synthesis of angiotensin II, following inhibition of RAAS, to increase vascular tone and arterial stiffness ([@B164]). However, limited data to assess the impact of vitamin D supplementation on the markers of arterial stiffness (PWV and AI) were inconclusive ([@B43], [@B165]), and may be due to inappropriate study design including insufficient duration of supplementation and insufficient power ([@B119]).

In contrast, Beveridge et al. ([@B21]) found no significant reduction in blood pressure after participants whose mean SBP was ≥140 mm Hg at baseline were supplemented with vitamin D. Of note, there are significant methodological differences in our approach. Beveridge et al. ([@B21]) included trials that combined vitamin D with antihypertensive drugs, administered large bolus doses to elderly populations, included subjects with resistant HTN, and/or supplemented with very low doses of vitamin D (i.e., 600 IU). These issues could mask any effects of vitamin D supplementation or simply not lead to any observable benefits. Our strict inclusion criteria resulted in the exclusion of 14 of the 27 studies that were analyzed by Beveridge et al. We had similar concerns with the meta-analysis conducted by Wang et al. ([@B26]) who reported that vitamin D supplementation led to a statistically significant increase in LDL and included RCTs that provided very low doses of vitamin D (i.e., 300 IU) or supplemented for durations considered too short (i.e., 42 days). Of the 12 studies included, and as mentioned by the authors, none were sufficiently powered to detect changes in CVD outcomes. The current meta-analysis revealed significant impact of vitamin D supplementation on lipid profiles with increased HDL and reduced LDL and TG.

Many observational studies support an association between cardiovascular risk factors and low vitamin D status. Perhaps most importantly, what constitutes vitamin D deficiency and repletion is somewhat debateable and, at times, contentious. The Institute of Medicine issues dietary recommendations, such as the Recommended Dietary Allowance (RDA), at the request of the U.S. and Canadian governments. In 2010, the Institute of Medicine set the RDA for vitamin D at 600 IU per day for individuals between the age of 1 and 70 ([@B48]). This RDA is assumed to achieve serum 25(OH)D levels of ≥50 nmol/l in 97.5% of the population. The methodology used to calculate this RDA, however, has been deemed erroneous ([@B166]) and estimates of much higher magnitude have been calculated by others -- 3,875 IU/day ([@B167]) to 8,895 IU/day ([@B168]).

Similarly, the definition of what is an "optimal" serum 25(OH)D concentration is also controversial. Serum 25(OH)D concentrations \>75 nmol/l ([@B12]) and \>80 nmol/l ([@B28]) have been suggested as necessary for lipid and cardiovascular health. Serum 25(OH)D concentrations of 100--150 are defined as optimal by the U.S. Endocrine Society with values below 75 nmol/l deemed insufficient ([@B169], [@B170]). The results of the present meta-analysis suggest that serum 25(OH)D concentrations ≥86 nmol/L are optimal for reductions in blood pressure, markers of arterial stiffness, and reductions in hs-CRP. It is important to note that these serum 25(OH)D concentrations were achieved with vitamin D supplement doses ≥4,000 IU/d---the current tolerable upper level of intake. Using the standards of the U.S. Endocrine Society, 27 of the 81 included studies in our meta-analyses reached optimal 25(OH)D levels post-supplementation, and only 16 had post-supplement 25(OH)D levels that were insufficient.

The duration of supplementation is an important factor in assessments of vitamin D. With a half-life of 2 months, to achieve and maintain a steady serum 25(OH)D concentration requires a follow-up period of at least 3 months. Here, we included trials that ranged from 3 months to 5 years of intervention in the meta-analysis. Somewhat surprisingly, we found better improvement in some outcomes (blood pressure and lipids) in trials that were less than 6 months, although this is likely related to higher compliance in short-term interventions ([@B171]). Improvements in blood pressure and lipid profile were also witnessed in a short, 3 month vitamin D intervention in obese PCOS patients ([@B116]). The women received 12,000 IU/d of vitamin D for an increase in their serum 25(OH)D of 50--168 nmol/L. In contrast, a 5 year trial of obese and vitamin D-insufficient prediabetics provided 2,800 IU/d of vitamin D found no change in blood pressure ([@B50]). It is known that overweight and obese individuals require two to three times the amount of vitamin D to increase serum 25(OH)D concentrations to the same extent as those with a normal BMI ([@B31], [@B47]).

The present study has several strengths and limitations. Even after enforcing a strict inclusion criteria, the included studies varied with regard to participant age, serum 25(OH)D concentrations at baseline, concurrent use of other nutrients or medication, and overall health status. We used a random-effect model and performed sensitivity analyses to mitigate these limitations. For some of the studies, cardiovascular outcomes of interest were secondary outcomes or the trial was not of sufficient power to detect a change in these outcomes. Many of the studies also did not describe dietary intakes, season of treatment, or sun exposure. Further, some included trials assessed relatively small populations (10--13 participants per intervention group), but taken together offer support to the larger trials. Strengths include the large sample and the consideration of a wide variety of CVD risk parameters from at least 28 clinical trials for each CVD outcome (with the exception of arterial PWV and AI).

Conclusion {#s5}
==========

Vitamin D deficiency is a highly prevalent condition and is independently associated with most CVD risk factors. The present meta-analysis demonstrated that vitamin D supplementation improved serum 25(OH)D concentrations significantly lowered blood pressure, serum PTH, hs-CRP, TC, LDL, and TG and increased HDL. Vitamin D supplementation also appears to improve arterial stiffness (PWV), but large and well-designed RCTs are required to confirm these findings. The present analysis suggests that for improvements in CVD risk factors vitamin D supplementation ≥4,000 IU/d and achieved serum 25(OH)D concentrations ≥86 nmol/L are required.
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